Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET...
Source: marketscreener.com